MicrobeWorld App

appsquarebannerad200x200

Microbes After Hours

WaterSupplyYouTubeFrame

Click for more "Microbes After Hours" videos

Join MicrobeWorld

Subscribe via Email

subscribe

Featured Image

Featured Video

Ebola Virus explained

Supporters

ASM House 200X200

FDA clears Novavax trial for anti-viral vaccine

Novavax Inc said the U.S. health regulator has given its clearance for an early-stage clinical trial of a vaccine to prevent respiratory syncytial virus infection, sending its shares up 7 percent in premarket trade.

In November, the U.S. Food and Drug Administration had put the trial on hold and asked the company a question about chemistry, manufacturing and controls, Novavax said.

Respiratory syncytial virus (RSV) is the most commonly identified cause of lower respiratory tract illnesses in infants and young children worldwide, the company said.

In August, the company had reported positive results from a pre-clinical study of the vaccine. [ID:nWNAB7130]
 
 

Comments (0)

Collections (0)

 

American Society for Microbiology
2012 1752 N Street, N.W. • Washington, DC 20036-2904 • (202) 737-3600
American Society For Microbiology © 2014   |   Privacy Policy   |   Terms of Use